Aug 17, 2026 earnings call — Record revenue, product growth and cash generation
Quarterly revenue surpassed $7 million while product revenue rose to approximately $900,000.
Revenue $0.0B (est $0.0B) · EPS $-0.12 (est $-2.00)
Key quotes
"During Q2, our commercial team added approximately 10 new distributor reps to the team they are working with."
"Our laboratory enables us to identify problems in the processes of diagnosing cancer. We then develop solutions, validate them in the real-world clinical laboratory and then commercialize those solutions to other laboratories."
Analyst Q&A 1
Large unusual share trades
Q (Adam Hutt · Leviticus Partners): He asked for commentary on the unusually high trading of about 800,000 shares in a 2-day period, where those shares came from and whether the company understands it.
A: They said they do not have more transparency into that trading and are as surprised as the analyst. They said they think it may reflect IR activities and investment conferences, and that computer algo trading is another factor that is very hard to trace.
"I think we're starting to see the fruits of some of the more IR activities that we're doing, participating in investment conferences." — Ilan Danieli (CEO)